TransCode Therapeutics, Inc. (RNAZ) 10-Year Financial Performance & Capital Metrics

RNAZ • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutTransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.Show more

Revenue $0
EBITDA -$15M +20.0%
Net Income -$17M +9.7%
EPS (Diluted) -47.14 +98.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -584.07 -68.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-81.78%

EPS CAGR

10Y-

5Y-

3Y-

TTM-647.37%

ROCE

10Y Avg-350.26%

5Y Avg-338.29%

3Y Avg-484.11%

Latest-505.04%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	42.47K	98.61K	516.75K	534.86K
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-42.47K	-98.61K	-516.75K	-534.86K
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-1.32%	-4.24%	-0.04%
Operating Expenses+	384.52K	456.87K	726.6K	6.11M	18.57M	18.9M	15.13M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	301.46K	230.56K	442.14K	3.35M	8.33M	6.64M	5.51M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	82.53K	226.31K	284.46K	2.75M	10.23M	12.26M	9.62M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-384K	-456.87K	-726.6K	-6.15M	-18.67M	-19.42M	-15.66M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.19%	-0.59%	-7.47%	-2.03%	-0.04%	0.19%
EBITDA+	0	-450.25K	-1.95M	-6.11M	-18.57M	-18.9M	-15.13M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-3.33%	-2.13%	-2.04%	-0.02%	0.2%
D&A (Non-Cash Add-back)	384K	0	0	42.47K	98.61K	516.75K	534.86K
EBIT	-384K	-450.25K	-1.95M	-6.75M	-17.56M	-18.49M	-16.73M
Net Interest Income+	0	-156.93K	-394.44K	-94.41K	-17.54M	-50.61K	-26.13K
Interest Income	68.92K	34	136	664	20.41K	5.29K	684
Interest Expense	0	156.97K	394.57K	95.07K	17.56M	55.9K	26.81K
Other Income/Expense	-69.44K	-150.35K	-1.62M	-692.26K	1.1M	872.42K	-1.09M
Pretax Income+	-453.44K	-607.21K	-2.34M	-6.84M	-17.56M	-18.55M	-16.75M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-453.44K	-607.21K	-2.34M	-6.84M	-17.56M	-18.55M	-16.75M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.34%	-2.86%	-1.92%	-1.57%	-0.06%	0.1%
Net Income (Continuing)	-453.44K	-607.21K	-2.34M	-6.84M	-17.56M	-18.55M	-16.75M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-2359.09	-72.00	-293.76	-648.00	-1080.00	-3453.53	-47.14
EPS Growth %	-	0.97%	-3.08%	-1.21%	-0.67%	-2.2%	0.99%
EPS (Basic)	-2359.09	-72.00	-293.76	-648.00	-73187.37	-3453.65	-47.14
Diluted Shares Outstanding	192	6.41K	7.98K	10.53K	16.22K	5.42K	356.12K
Basic Shares Outstanding	192	6.41K	7.98K	10.53K	16.22K	5.42K	356.12K
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	214.65K	204.47K	831.22K	22.73M	7.38M	4.46M	7.09M
Cash & Short-Term Investments	212.98K	204.47K	828.02K	20.83M	4.98M	2.77M	5.81M
Cash Only	212.98K	204.47K	828.02K	20.83M	4.97M	2.77M	5.81M
Short-Term Investments	0	0	0	0	9.41K	0	0
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	1.84M	1.02M	1.14M	517.48K
Total Non-Current Assets+	0	12.27K	224.15K	206.27K	208.58K	714.26K	201.16K
Property, Plant & Equipment	0	0	0	206.27K	208.58K	602.4K	89.31K
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	12.27K	0	0	0	0	0
Other Non-Current Assets	0	0	224.15K	0	0	111.86K	111.86K
Total Assets+	214.65K	216.74K	1.06M	22.94M	7.59M	5.17M	7.29M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	0.01%	3.87%	20.74%	-0.67%	-0.32%	0.41%
Total Current Liabilities+	117.68K	62.94K	404.86K	2.53M	4.35M	3.49M	2.77M
Accounts Payable	0	27.26K	0	2.02M	0	0	2.58M
Days Payables Outstanding	-	-	-	17.33K	-	-	1.76K
Short-Term Debt	35.69K	0	0	0	0	0	38.29K
Deferred Revenue (Current)	0	0	0	30.53K	0	27.06K	0
Other Current Liabilities	0	35.69K	-1	-2.02M	0	0	26.11K
Current Ratio	1.82x	3.25x	2.05x	8.97x	1.70x	1.28x	2.56x
Quick Ratio	1.82x	3.25x	2.05x	8.97x	1.70x	1.28x	2.56x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	600.93K	1.25M	4.06M	0	0	38.29K	6.54M
Long-Term Debt	436.21K	927.81K	2.09M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	38.29K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	164.72K	323.5K	1.97M	0	0	0	6.54M
Total Liabilities	718.61K	1.31M	4.46M	2.53M	4.35M	3.53M	9.31M
Total Debt+	471.9K	927.81K	2.09M	0	0	450.57K	38.29K
Net Debt	258.92K	723.34K	1.26M	-20.83M	-4.97M	-2.32M	-5.77M
Debt / Equity	-	-	-	-	-	0.27x	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-2.91x	-1.84x	-64.70x	-1.06x	-347.39x	-584.07x
Total Equity+	-503.97K	-1.1M	-3.41M	20.4M	3.24M	1.64M	-2.02M
Equity Growth %	-	-1.18%	-2.11%	6.99%	-0.84%	-0.49%	-2.23%
Book Value per Share	-2621.96	-171.30	-427.15	1937.37	199.78	302.49	-5.67
Total Shareholders' Equity	-503.97K	-1.1M	-3.41M	20.4M	3.24M	1.64M	-2.02M
Common Stock	764	764	464	1.29K	2	63	103
Retained Earnings	-510.78K	-1.12M	-3.46M	-10.31M	-27.87M	-46.42M	-63.2M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-11.8K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-299.57K	-508.51K	-492.97K	-5.27M	-15.76M	-18.07M	-13.34M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.7%	0.03%	-9.68%	-1.99%	-0.15%	0.26%
Net Income	-453.44K	-607.21K	-2.34M	-6.84M	-17.56M	-18.55M	-16.75M
Depreciation & Amortization	0	0	0	42.47K	98.61K	516.75K	534.86K
Stock-Based Compensation	22.38K	1.4K	45.44K	186K	0	1.04M	1.7M
Deferred Taxes	0	0	0	876.19K	0	0	0
Other Non-Cash Items	106.55K	102.01K	1.5M	39.47K	395.33K	0	1.54M
Working Capital Changes	24.94K	-4.7K	309.76K	432.39K	1.31M	-1.08M	-351.48K
Change in Receivables	0	0	0	0	-360.23K	360.23K	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	0	-54.74K	191.25K	2.29M	1.84M	0	0
Cash from Investing+	0	0	0	-251.82K	-100.92K	-35.61K	-21.76K
Capital Expenditures	0	0	0	-254.82K	-100.92K	-35.61K	-21.76K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	512.43K	500K	1.12M	25.52M	5.99K	15.91M	16.4M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	-37.57K	0	-73.48K	-818.55K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-299.57K	-508.51K	-492.97K	-5.52M	-15.86M	-18.11M	-13.36M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.7%	0.03%	-10.2%	-1.87%	-0.14%	0.26%
FCF per Share	-1558.57	-79.37	-61.78	-524.28	-977.96	-3338.63	-37.51
FCF Conversion (FCF/Net Income)	0.66x	0.84x	0.21x	0.77x	0.90x	0.97x	0.80x
Interest Paid	0	0	0	17.87K	0	32.86K	16.63K
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-80.53%	-148.57%	-759.85%	-
Debt / Equity	-	-	-	-	-	0.27x	-
Interest Coverage	-	-2.91x	-1.84x	-64.70x	-1.06x	-347.39x	-584.07x
FCF Conversion	0.66x	0.84x	0.21x	0.77x	0.90x	0.97x	0.80x

Frequently Asked Questions

Growth & Financials

TransCode Therapeutics, Inc. (RNAZ) grew revenue by 0.0% over the past year. Growth has been modest.

TransCode Therapeutics, Inc. (RNAZ) reported a net loss of $27.1M for fiscal year 2024.

Dividend & Returns

TransCode Therapeutics, Inc. (RNAZ) had negative free cash flow of $14.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener